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The UK Parliamentary and Health Service Ombudsman inquiry
“Time to Act” found failures in the recognition, diagnosis, and
early management of those who died from sepsis,1 which
triggered this guidance. In sepsis the body’s immune and
coagulation systems are switched on by an infection and cause
one or more body organs to malfunction with variable severity.
The condition is life threatening. Although most people with
infection do not have and will not develop sepsis, non-specific
signs and symptoms can lead to late recognition of people who
might have sepsis. We would like clinicians to “think sepsis”
and recognise symptoms and signs of potential organ failure
when they assess someone with infection, in a similar way to
thinking “Could this chest pain be cardiac in origin?”
This guidance provides a pragmatic approach for patients with
infection who are assessed in the community, emergency
departments, and hospitals by a wide range of general and
specialist healthcare professionals. It includes guidance on
assessment of risk factors followed by a detailed structured
assessment of potential clinical signs and symptoms of concern.
Definitions of sepsis have been developed,2 but these offer
limited explanation on how to confirm or rule out the diagnosis
in general clinical settings or in the community.3 Current
mechanisms to diagnose sepsis and guidelines for use largely
apply to critical care settings such as intensive care.2 We
recognised a need for better recognition of sepsis in
non-intensive settings and for the diagnosis to be entertained
sooner.
While sepsis is multifactorial and rarely presents in the same
way, the Guideline Development Group considered that use of
an easy, structured risk assessment may help clinicians identify
those most severely ill who require immediate potentially
lifesaving treatment. This guideline ensures that patients defined
as having sepsis by recent definitions are, as a minimum,
assessed as moderate-high risk.2 This guidance is also about
appropriate de-escalation if sepsis is unlikely and broad spectrum
antibiotics or hospital admission are not appropriate.
This article summarises recommendations from the National
Institute for Health and Care Excellence (NICE) guideline for
the recognition, diagnosis, andmanagement of sepsis in children
and adults.4 Recommendations and the clinical pathway are
available via the NICE website, and the UK Sepsis Trust tools
are being revised to align with this guidance.5 This article is
accompanied by an infographic, which displays the NICE
guideline as a decision making tool.
Recommendations
NICE recommendations are based on systematic reviews of best
available evidence and explicit consideration of cost
effectiveness. When minimal evidence is available,
recommendations are based on the Guideline Development
Group’s (GDG) experience and opinion of what constitutes
good practice.
Think sepsis
• People with sepsis may have non-specific, non-localised
presentations—such as feeling very unwell—and may not
necessarily have a high temperature. [Based on the
experience and the opinion of the GDG]
• Pay particular attention to concerns expressed by the patient
and his or her family or carers, such as changes from usual
behaviour. Take extra care when people cannot give a good
history, such as people with English as a second language
or with communication problems. [Based on the experience
and opinion of the GDG]
• Assess people with any suspected infection to identify:
–The possible source of infection
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What you need to know
• “Think sepsis” in any person with suspected infection
• Sepsis may present with non-specific symptoms and signs and without fever
• Have a high index of suspicion of sepsis in those who are aged <1 year or >75 years, pregnant, or immunocompromised, and those
who have a device or line in situ or have had recent surgery
• Use risk factors and any indicators of clinical concern to decide if full assessment is required
• Offer people at high risk of sepsis broad spectrum antibiotics and intravenous fluids in hospital
–Factors that increase risk of sepsis (see box 1)
–Any signs that are indicators for clinical concern, such
as new onset abnormalities of behaviour, circulation, or
respiration.
[Based on the experience and opinion of the GDG]
• If making a remote assessment, identify factors that
increase risk of sepsis (see box 1) or indications of clinical
concern (such as new onset abnormalities of behaviour,
circulation, or respiration) when deciding whether to offer
a face-to-face assessment and the urgency of the
assessment. [Based on the experience and opinion of the
GDG]
• Use a structured set of observations to assess people in a
face-to-face setting to stratify risk if there is clinical
concern and sepsis is suspected. Consider using an early
warning score to assess people with suspected sepsis in
acute hospital settings. [Based on the experience and
opinion of the GDG]
• Suspect neutropenic sepsis in patients who are having
anticancer treatment and become unwell, and refer them
immediately for assessment in secondary or tertiary care
(see NICE clinical guideline CG151 on neutropenic
sepsis6). [Based on evidence underpinning the NICE clinical
guideline on neutropenic sepsis (CG151)]
Risk stratification
The GDG found evidence of low quality and used this as the
starting point for their recommendations. If a person has
infection and there is clinical concern that he or she might have
sepsis, perform a structured assessment using the history and
physical examination to grade risk of severe illness or death
from sepsis (see infographic).
• Changes in behaviour, in particular a new altered mental
state, are a strong risk factor for mortality [Based on very
low quality evidence from observational studies and the
experience and opinion of the GDG]
• Increased respiratory rate is associated with poor patient
outcome and diagnosis of infection, particularly because
pneumonia is a common cause of sepsis
• Extreme values of blood pressure are a cause of clinical
concern. However, blood pressure should be interpreted
in the context of a person’s previous blood pressure if this
is known [Based on very low quality evidence from
observational studies and the experience and opinion of
the GDG]
• Tachycardia is a risk factor for serious infections and
sepsis, and for admission to intensive care and mortality
[Based on very low quality evidence from observational
studies and the experience and opinion of the GDG]
• Fever may be a risk factor for sepsis, although some studies
showed that a high proportion of patients with sepsis did
not have a temperature. In particular, elderly people, people
receiving cancer treatment, and those who are severely
unwell with sepsis are less likely to develop a raised
temperature. [Based on very low quality evidence from
observational studies and the experience and opinion of
the GDG]
–Very high temperature is unusual in children, and
therefore it is often indicative of bacterial infection.
[Based on evidence underpinning the NICE guideline on
fever under 5s (CG160)7]
• Mottled or ashen appearance; cyanosis of skin, lips, or
tongue; and a non-blanching rash of skin are markers of
high risk for severe illness or death. [Based on evidence
underpinning the NICE guidelines on meningitis and
meningococcal septicaemia (CG102)8 and fever in under
5s (CG160)7]
Early management of people with suspected
sepsis
The management pathway depends on setting, patient’s age,
and outcome of the structured assessment. Again, the evidence
base was generally of low quality.
Setting
Outside hospital, people with a low risk of illness or death
following structured assessment can bemanaged in a community
setting and should not be referred to hospital. People with
moderate to high risk may be managed outside acute hospital
settings depending on clinical assessment. All those with high
risk of illness or death from suspected sepsis should be referred
to hospital.
In acute hospital settings, the recommendations are similar. For
people at highest risk of illness or death from suspected sepsis,
a senior doctor or nurse should review the patient immediately.
They may make an alternative diagnosis and avoid the
inappropriate use of broad spectrum antibiotics.
Management
Those classified as having a high risk of sepsis require
antibiotics and fluids and potentially other supportive care.
Treatment must be delivered in a timely fashion andmay require
specialist and critical care input. Use point of care lactate testing
to guide fluid therapy and potential involvement of critical care.
If a definitive condition or infection cannot be identified,
structured reassessment should be repeated. The management
of suspected sepsis without any high or moderate to high risk
criteria should be based on clinical judgment.
Source of infection
As part of the initial assessment, look for a source of infection,
including sources that might need surgical drainage. Target
testing according to history and examination—for example,
urine analysis for those with suspected urinary tract sepsis.
Imaging of the abdomen and pelvis should be considered if no
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Box 1: Factors that increase the risk of sepsis
People in the following groups are at increased risk of developing sepsis
• People <1 year old or >75 years old, or very frail people
• People who have impaired immune systems because of illness or drugs:
– Chemotherapy for cancer treatment
– Impaired immune function (such as those with diabetes or sickle cell disease, or people who have had a splenectomy)
– Long term treatment with corticosteroids
– Treatment with immunosuppressant drugs for non-malignant disorders, such as rheumatoid arthritis
• People who have had surgery, or other invasive procedures, in the past six weeks
• People with any breach of skin integrity (such as cuts, burns, blisters, or skin infections)
• Injecting drug misuse
• People with indwelling lines or catheters.
• Women who are pregnant or have given birth or had a termination of pregnancy or miscarriage in the past six weeks, in particular,
women who
– Have impaired immune systems because of illness or drugs
– Have gestational diabetes or diabetes or other comorbidities
– Needed invasive procedures (such as caesarean section, forceps delivery, removal of retained products of conception)
– Had a prolonged rupture of membranes
– Either have or have been in close contact with people with group A streptococcal infection (such as scarlet fever)
– Have continued vaginal bleeding or an offensive vaginal discharge
• Neonates, particularly if there has been:
– Invasive group B streptococcal infection in a previous baby
– Maternal group B streptococcal colonisation, bacteriuria, or infection in the current pregnancy
– Prelabour rupture of membranes
– Preterm birth after spontaneous labour (before 37 weeks’ gestation)
– Suspected or confirmed rupture of membranes for >18 hours in a preterm birth
– Maternal intrapartum fever >38°C, or confirmed or suspected chorioamnionitis
– Parenteral antibiotic treatment given to the woman for confirmed or suspected invasive bacterial infection (such as septicaemia) at
any time during labour or in the 24 hour periods before and after the birth (this does not refer to intrapartum antibiotic prophylaxis)
– Suspected or confirmed infection in another baby in the case of a multiple pregnancy
likely source is identified after clinical examination and initial
tests. [Based on knowledge of the epidemiology of causes, and
the experience and opinion of the GDG]
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Guidelines into practice
• Do you “think sepsis” for everyone who presents with suspected infection?
• Do you use a structured assessment for anyone with risk factors for sepsis and clinical abnormalities?
• Among those assessed in hospital with suspected sepsis, has a senior doctor reviewed the patient immediately if highest risk factors
are present?
• Are those at high risk from sepsis offered intravenous antibiotics and fluid resuscitation within one hour of assessment?
How patients were involved in the creation of this article
Lay members joined the committee to form the recommendations summarised here. Patient organisations including the UK Sepsis Trust,
MRSA Action UK, Group B Strep Support, Fiona Elizabeth Agnew Trust, and Meningitis Research Foundation were among the registered
stakeholders that were consulted at both scoping and development stages.
Their involvement shaped the scope of the guideline and questions to be asked, and two lay members were full members of the committee.
The UK Sepsis Trust has produced clinical tools to aid guideline implementation.
Further information on the guidance
Methods
The Guideline Development Group (GDG) comprised a consultant in paediatric immunology and infectious diseases (chair), two consultants
in intensive care medicine (including one in paediatrics), two consultants in emergency medicine (including one in paediatrics), a chair in
paediatric infection, a corporate matron in patient safety, a consultant in acute and critical care medicine, a general practitioner, an acute
physician/senior clinical research lead, a paediatric development manager (paramedic), and two lay members. Co-opted experts included
a consultant in obstetrics and a consultant in medical microbiology.
The guideline was developed using standard National Institute for Health and Care Excellence (NICE) guideline methodology (www.nice.
org.uk/article/pmg20/chapter/1%20introduction%20and%20overview). The GDG developed clinical questions, collected and appraised
clinical evidence, and evaluated the cost effectiveness of proposed interventions and management strategies through literature review and
economic considerations where possible. Quality ratings of the evidence were based on GRADE methodology (www.gradeworkinggroup.
org). These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study. Where standard
methods could not be applied, a customised quality assessment was done.
Limited evidence exists for identification and early management of sepsis in primary care or the emergency department, and only some of
the critical care evidence was relevant or interpretable in a meaningful way for non-critical care settings.
Future research
• Can early warning scores, such as NEWS (national early warning scores for adults) and PEWS (paediatric early warning score), be
used to improve the detection of sepsis in pre-hospital settings, and in emergency departments?
• Is it possible to derive and validate a set of clinical decision rules or a predictive tool to rule out sepsis which can be applied to patients
presenting to hospital with suspected sepsis?
• What is the clinical and cost effectiveness of procalcitonin (PCT) point of care tests at initial triage for diagnosis of serious infection
and the initiation of appropriate antibiotic therapy?
• What are the incidence, presentation, and management of sepsis in the United Kingdom?
• What is the association between the NICE sepsis guideline and patient care processes and outcomes over the next five years?
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